Project Grant K99AG086600
Award Date
6/15/25
Completion Date
5/31/27
Dollars Obligated
$133K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will provide $2,488,671.00 from September 1, 2024 through June 30, 2029 to Washington University in St. Louis to conduct research on the impact of inherited and modifiable risk factors on clonal hematopoiesis (CH) and its association with age-related diseases like cardiovascular disease and Alzheimer's disease. The study will leverage longitudinal data from large biobanks and cohorts to characterize...
This Project Grant award of $2,653,601 from the National Institute on Aging (NIA) under the Aging Research Federal Grant Program (CFDA 93.866) supports research to identify genetic, environmental, and molecular factors that influence the rate of clonal hematopoiesis (CH) expansion and associated health outcomes across the human lifespan. The key objectives are to: 1) apply a computational method to estimate CH expansion rates in over 1.6 million individuals to identify genetic factors conferring...
This Project Grant award from the National Institute on Aging (NIA) under CFDA 93.866, Aging Research, aims to investigate how epigenetic deregulation of osteoblasts (bone cells) promotes age-related clonality in hematopoietic cells. The $1,335,986 award to The Trustees of Columbia University in the City of New York, with a performance period from Aug 2024 to Apr 2029, will support research to: Delineate how epigenetically modified mouse and human stromal cells and osteoblasts promote the...
This $153,696.00 Project Grant award from the National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), supports research aimed at elucidating the developmental origins and functional characteristics of myeloid-biased hematopoietic stem cells (HSCs) that emerge during fetal development. The principal investigator at The Leland Stanford Junior University will utilize advanced techniques such as flow cytometry, immunofluorescence, transplantation, and...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will provide $2,149,861 to the Albert Einstein College of Medicine to investigate the relationship between clonal hematopoiesis (CH), aging, and exceptional longevity. The key objectives are to: Determine the prevalence and mutational spectrum of CH and its association with age-related diseases in populations with exceptional longevity, comparing centenarians, their offspring, and age/sex-matched...
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) will support a study to examine the role of clonal somatic mutations in microglia and their contribution to the pathogenesis of Alzheimer's disease (AD). The $2,672,344 award to The Children's Hospital Corporation, doing business as Boston Children's Hospital, will be used to: 1) identify somatic mutations through re-analysis of existing AD cohort datasets, 2) screen for somatic mutations in genes...
This Project Grant award from the National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), is focused on identifying and characterizing clonal expansions that increase with age across various tissues, and understanding how these clonal mosaicism patterns are influenced by aging and age-related diseases. The $159,492 award to Weill Medical College of Cornell University aims to (1) develop tools to accurately identify somatic variants from publicly available...
This federal Project Grant award of $126,830 from the National Human Genome Research Institute (CFDA 93.172 - Human Genome Research) supports research to develop a somatic mutation-resolved lineage tracing system. The project aims to reconstruct single-cell genealogical trees and detect associated somatic mutations and epigenetic alterations. This will enable investigations into the impact of genomic modifications on the evolutionary dynamics of hematopoietic stem cells, including during...
This federal Project Grant award, valued at $166,644.00 and awarded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the functional and molecular consequences of aging and TET2 mutations on human hematopoietic stem cell responses to inflammatory cytokines like IL-1β. The research aims to provide a comprehensive understanding of how these factors alter inflammatory response pathways, leading...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $299,781 to Mogling Bio Inc. to develop a therapeutic regimen that can attenuate aging of human hematopoietic stem cells (HSCs). The central goal is to validate the use of the drug CASIN to restore CDC42-regulated polarity and rejuvenate aged human HSCs ex vivo. This research aims to benefit bone marrow HSC transplant patients...